GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viking Therapeutics Inc (NAS:VKTX) » Definitions » E10

Viking Therapeutics (Viking Therapeutics) E10 : $-1.72 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Viking Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Viking Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was $-0.260. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-1.72 for the trailing ten years ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-06-05), Viking Therapeutics's current stock price is $57.60. Viking Therapeutics's E10 for the quarter that ended in Mar. 2024 was $-1.72. Viking Therapeutics's Shiller PE Ratio of today is .


Viking Therapeutics E10 Historical Data

The historical data trend for Viking Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viking Therapeutics E10 Chart

Viking Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -1.57 -1.67

Viking Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.62 -1.65 -1.69 -1.67 -1.72

Competitive Comparison of Viking Therapeutics's E10

For the Biotechnology subindustry, Viking Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viking Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viking Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Viking Therapeutics's Shiller PE Ratio falls into.



Viking Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Viking Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.26/131.7762*131.7762
=-0.260

Current CPI (Mar. 2024) = 131.7762.

Viking Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201406 -5.286 100.560 -6.927
201409 -0.061 100.428 -0.080
201412 0.322 99.070 0.428
201503 -0.624 99.621 -0.825
201506 -1.070 100.684 -1.400
201509 -0.530 100.392 -0.696
201512 -0.560 99.792 -0.739
201603 -0.400 100.470 -0.525
201606 -0.220 101.688 -0.285
201609 -0.200 101.861 -0.259
201612 -0.180 101.863 -0.233
201703 -0.230 102.862 -0.295
201706 -0.210 103.349 -0.268
201709 -0.220 104.136 -0.278
201712 -0.140 104.011 -0.177
201803 -0.100 105.290 -0.125
201806 -0.130 106.317 -0.161
201809 -0.110 106.507 -0.136
201812 -0.070 105.998 -0.087
201903 -0.070 107.251 -0.086
201906 -0.110 108.070 -0.134
201909 -0.080 108.329 -0.097
201912 -0.110 108.420 -0.134
202003 -0.130 108.902 -0.157
202006 -0.130 108.767 -0.158
202009 -0.130 109.815 -0.156
202012 -0.150 109.897 -0.180
202103 -0.190 111.754 -0.224
202106 -0.200 114.631 -0.230
202109 -0.170 115.734 -0.194
202112 -0.160 117.630 -0.179
202203 -0.210 121.301 -0.228
202206 -0.230 125.017 -0.242
202209 -0.210 125.227 -0.221
202212 -0.260 125.222 -0.274
202303 -0.250 127.348 -0.259
202306 -0.190 128.729 -0.194
202309 -0.230 129.860 -0.233
202312 -0.250 129.419 -0.255
202403 -0.260 131.776 -0.260

Add all the adjusted EPS together and divide 10 will get our e10.


Viking Therapeutics  (NAS:VKTX) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Viking Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Viking Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Viking Therapeutics (Viking Therapeutics) Business Description

Traded in Other Exchanges
Address
9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, USA, 92121
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Executives
Sarah Kathryn Rouan director 4995 BRADENTON AVENUE, SUITE 240, DUBLIN OH 43017
Greg Zante officer: Chief Financial Officer C/O SANGAMO BIOSCIENCES, INC STE-A-100, POINT RICHMOND TECH, 501 CANAL BLVD,, RICHMOND CA 94804
Rowland Charles A Jr director 3338 LANCASHIRE RD, FURLONG PA 18925
Lawson Macartney director C/O AMBRX, INC., 10975 N. TORREY PINES RD., LA JOLLA CA 92037
Brian Lian director, officer: President & CEO C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Marianna Mancini officer: Chief Operating Officer C/O VIKING THERAPEUTICS, INC., 12340 EL CAMINO REAL, STE 250, SAN DIEGO CA 92130
Matthew W Foehr director 11119 NORTH TORREY PINES RD #200, LA JOLLA CA 92037
Ligand Pharmaceuticals Inc 10 percent owner 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO CA 92121
Hiroko Masamune officer: Chief Development Officer C/O VIKING THERAPEUTICS, INC., 12340 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
Michael Morneau officer: Chief Financial Officer C/O TRIUS THERAPEUTICS, INC., 6410 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
J Matthew Singleton director 286 STANWICH ROAD, GREENWICH CT 06830
Stephen W Webster director C/O OPTIMER PHARMACEUTICALS, INC, 101 HUDSON STREET, SAN DIEGO CA 07302
Rochelle Hanley officer: Chief Medical Officer C/O VIKING THERAPEUTICS, INC., 11119 NORTH TORREY PINES ROAD, SUITE 50, SAN DIEGO CA 92037
Michael Dinerman officer: Chief Operating Officer C/O VIKING THERAPEUTICS, INC., 11119 NORTH TORREY PINES ROAD, SUITE 50, SAN DIEGO CA 92037